Efficacy and Safety of Efgartigimod for Patients With Myasthenia Gravis in a Real‐World Cohort of 77 Patients
Efgartigimod safely improved MG-ADL scores and reduced steroid use across MG subtypes, with sustained efficacy through multiple treatment cycles. These findings support its potential when conventional therapies fail.
Authors
- Rongjing Guo
- Zhe Ruan (ORCID: https://orcid.org/0000-0002-8190-4022)
- Ting Chang (ORCID: https://orcid.org/0000-0002-7546-8017)
- Huanhuan Li (ORCID: https://orcid.org/0000-0003-0917-4472)
- Yu Liu (ORCID: https://orcid.org/0000-0002-5603-2971)
- Qingqing Wang (ORCID: https://orcid.org/0000-0003-3256-9958)
- Chao Sun (ORCID: https://orcid.org/0000-0002-9046-3142)
- Ting Gao (ORCID: https://orcid.org/0000-0001-5360-1019)
- Zhuyi Li (ORCID: https://orcid.org/0000-0002-6877-3304)
- Xiaoxi Huang (ORCID: https://orcid.org/0000-0003-2512-3157)
- Yonglan Tang
- Xiangqi Cao
- Shibo Hao
Institutions
- Air Force Medical University (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/cns.70391
- Citations
- 6
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 8.34
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China